X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Orchid Chemicals with Sun Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ORCHID PHARMA LTD vs SUN PHARMA - Comparison Results

ORCHID PHARMA LTD    Change

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ORCHID PHARMA LTD SUN PHARMA ORCHID PHARMA LTD/
SUN PHARMA
 
P/E (TTM) x -0.5 25.2 - View Chart
P/BV x 0.4 3.7 9.9% View Chart
Dividend Yield % 0.0 0.6 -  

Financials

 ORCHID PHARMA LTD   SUN PHARMA
EQUITY SHARE DATA
    ORCHID PHARMA LTD
Sep-13
SUN PHARMA
Mar-17
ORCHID PHARMA LTD/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs194842 23.0%   
Low Rs35572 6.1%   
Sales per share (Unadj.) Rs276.5131.6 210.1%  
Earnings per share (Unadj.) Rs-79.232.7 -242.2%  
Cash flow per share (Unadj.) Rs-43.538.0 -114.4%  
Dividends per share (Unadj.) Rs03.50 0.0%  
Dividend yield (eoy) %00.5 0.0%  
Book value per share (Unadj.) Rs53.9152.7 35.3%  
Shares outstanding (eoy) m70.452,399.26 2.9%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x0.45.4 7.7%   
Avg P/E ratio x-1.421.6 -6.7%  
P/CF ratio (eoy) x-2.618.6 -14.1%  
Price / Book Value ratio x2.14.6 45.8%  
Dividend payout %010.7 0.0%   
Avg Mkt Cap Rs m8,0671,696,877 0.5%   
No. of employees `0002.817.5 16.0%   
Total wages/salary Rs m2,52749,023 5.2%   
Avg. sales/employee Rs Th6,956.118,028.3 38.6%   
Avg. wages/employee Rs Th902.52,798.8 32.2%   
Avg. net profit/employee Rs Th-1,993.04,479.5 -44.5%   
INCOME DATA
Net Sales Rs m19,477315,784 6.2%  
Other income Rs m4076,232 6.5%   
Total revenues Rs m19,884322,016 6.2%   
Gross profit Rs m1,103100,893 1.1%  
Depreciation Rs m2,51912,648 19.9%   
Interest Rs m5,2273,998 130.7%   
Profit before tax Rs m-6,23690,479 -6.9%   
Minority Interest Rs m200-   
Prior Period Items Rs m099 0.0%   
Extraordinary Inc (Exp) Rs m5110-   
Tax Rs m-12512,116 -1.0%   
Profit after tax Rs m-5,58078,462 -7.1%  
Gross profit margin %5.731.9 17.7%  
Effective tax rate %2.013.4 15.0%   
Net profit margin %-28.724.8 -115.3%  
BALANCE SHEET DATA
Current assets Rs m11,014329,537 3.3%   
Current liabilities Rs m32,060178,870 17.9%   
Net working cap to sales %-108.147.7 -226.5%  
Current ratio x0.31.8 18.6%  
Inventory Days Days9579 120.1%  
Debtors Days Days3483 40.3%  
Net fixed assets Rs m29,440204,766 14.4%   
Share capital Rs m7052,399 29.4%   
"Free" reserves Rs m2,043363,997 0.6%   
Net worth Rs m3,800366,397 1.0%   
Long term debt Rs m9,01814,361 62.8%   
Total assets Rs m46,510614,102 7.6%  
Interest coverage x-0.223.6 -0.8%   
Debt to equity ratio x2.40 6,054.9%  
Sales to assets ratio x0.40.5 81.4%   
Return on assets %-0.813.4 -5.7%  
Return on equity %-146.921.4 -685.8%  
Return on capital %-3.724.8 -15.0%  
Exports to sales %37.90-   
Imports to sales %22.60-   
Exports (fob) Rs m7,378NA-   
Imports (cif) Rs m4,406NA-   
Fx inflow Rs m7,51344,118 17.0%   
Fx outflow Rs m5,64924,484 23.1%   
Net fx Rs m1,86519,634 9.5%   
CASH FLOW
From Operations Rs m1,68270,822 2.4%  
From Investments Rs m-9,860-42,216 23.4%  
From Financial Activity Rs m6,644-22,854 -29.1%  
Net Cashflow Rs m-1,5356,107 -25.1%  

Share Holding

Indian Promoters % 32.3 63.7 50.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 4.6 5.1 89.7%  
FIIs % 3.3 23.0 14.3%  
ADR/GDR % 4.6 0.0 -  
Free float % 55.3 8.3 666.3%  
Shareholders   84,811 133,026 63.8%  
Pledged promoter(s) holding % 54.9 0.5 10,362.3%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ORCHID PHARMA LTD With:   GSK PHARMA  ASTRAZENECA PHARMA  DISHMAN PHARMA  PIRAMAL ENTERPRISES  NATCO PHARMA  

Compare ORCHID PHARMA LTD With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes Marginally Lower; Capital Goods & Realty Stocks Fall(Closing)

Indian share markets witnessed selling pressure in the final hour of trade to finish just below the dotted line. At the closing bell, the BSE Sensex closed lower by 71 points.

Related Views on News

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

May 30, 2017

US markets decline while other geographies grow in the quarter.

Sun Pharma: Slow Growth Across Major Markets (Quarterly Results Update - Detailed)

Mar 11, 2017

Sun Pharma has announced its December quarter (3QFY17) results. The company has reported 8% YoY growth in sales and a decline of 4.7% YoY in the net profits.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

Follow India's Super Investors to Make Big Money in the Market Crash(The 5 Minute Wrapup)

Feb 8, 2018

Has the sell-off in the markets left India's super investors unduly worried?

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

Rising Dominance of Mutual Funds(Chart Of The Day)

Feb 8, 2018

Domestic money flow into Indian equities surpassed foreign fund flows in the recent years. But will it continue in volatile market?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ORCHID PHARMA LTD SHARE PRICE


Feb 20, 2018 (Close)

TRACK ORCHID PHARMA LTD

  • Track your investment in ORCHID PHARMA LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ORCHID PHARMA LTD

ORCHID PHARMA LTD - PIRAMAL ENTERPRISES COMPARISON

COMPARE ORCHID PHARMA LTD WITH

MARKET STATS